Laurus Labs – Can Business Transform to Next Level?

Dear All,

I have few questions as follows:

1. Can we assume there was no paxlovid sale during the quarter ending Dec’23? Or safe to assume quarterly run rate of 640 cr for CS going forward?

My aim is to know safe assumption on CS base ex-paxlovid going forward.

2. Less margin contraction compared to Divis, is it right interpretation that some other CS projects are supporting the margin?

3. Since CS will have FY24 year of consolidation, should we expect decent growth from FDF and API business exc ARV as pricing pressure eases?

Disc: Invested